Previous 10 | Next 10 |
home / stock / msclf / msclf news
Toronto, Ontario--(Newsfile Corp. - March 29, 2023) - Satellos Bioscience Inc. ( TSXV: MSCL ) ( OTCQB: MSCLF ) (" Satellos " or the " Company "), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dys...
Toronto, Ontario--(Newsfile Corp. - March 22, 2023) - Satellos Bioscience Inc. ( TSXV: MSCL ) ( OTCQB: MSCLF ) (" Satellos " or the " Company "), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dys...
Ryan Mitchell, PhD and Director of Business Development at Satellos to highlight SAT-3153 and Satellos' novel muscle regeneration technology in two forums at this year's MDA Conference and Summit Toronto, Ontario--(Newsfile Corp. - March 17, 2023) - Satellos Bioscience Inc. ( TSXV: MSCL ) ( OTCQ...
Toronto, Ontario--(Newsfile Corp. - March 15, 2023) - Satellos Bioscience Inc. ( TSXV: MSCL ) ( OTCQB: MSCLF ) (" Satellos " or the " Company "), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscula...
Toronto, Ontario--(Newsfile Corp. - March 10, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) (" Satellos " or the " Company "), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystr...
- 40% increase in muscle size compared to control mice - 25% increase in muscle force, approaching levels seen in normal mice Toronto, Ontario--(Newsfile Corp. - February 6, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) (" Satellos " or the " Company "), a drug dis...
- SAT-3153 Designated for pre-IND Studies - Toronto, Ontario--(Newsfile Corp. - January 3, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) (" Satellos " or the " Company "), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to t...
Toronto, Ontario--(Newsfile Corp. - November 23, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Corporation "), a drug discovery company developing therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, annou...
-Proof of concept studies to be completed by YE- Toronto, Ontario--(Newsfile Corp. - November 3, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Company "), a drug discovery company developing therapeutics to regenerate muscle as a new approach to treating disease condi...
- Advancements on the Company's evaluation of potential new disease indication Toronto, Ontario--(Newsfile Corp. - October 11, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Company "), a drug discovery company aimed at developing therapeutics that regenerate muscle as...
News, Short Squeeze, Breakout and More Instantly...
– Investigational New Drug (IND) enabling preclinical and toxicology studies successfully completed – Initiation of a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience Inc. (“Satellos” or the “Company”) ...
–SAT-3247 treatment improved muscle repair and regeneration in canine model of DMD – SAT-3247 treatment also improved muscle force in this canine model of DMD – Satellos remains on track to initiate a Phase 1 clinical trial in Q3 2024 Satellos Bios...
– Frank Gleeson, Satellos CEO, to participate in a panel discussion titled "Research Row: PPMD Moving the Needle" on June 29, 2024 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company d...